8-K: Amicus Stockholders Approve BioMarin Merger

Amicus Therapeutics stockholders overwhelmingly approved the company's acquisition by BioMarin Pharmaceutical Inc. at a special meeting held on March 3, 2026.

Summary

• Amicus Therapeutics, Inc. stockholders approved the pending acquisition by BioMarin Pharmaceutical Inc. at a virtual special meeting on March 3, 2026.
• The Merger Proposal, adopting the Agreement and Plan of Merger dated December 19, 2025, was approved with 234,593,492 votes For, 119,194 Against, and 72,557 Abstentions.
• The non-binding, advisory Compensation Proposal for named executive officers related to the Merger was also approved with 209,150,012 votes For, 24,282,220 Against, and 1,353,011 Abstentions.
• Approximately 74.79% of eligible shares (234,785,243 out of 313,918,463) were present and voted at the meeting.
• Stockholder approval satisfies a key closing condition for the Merger.
• Early termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period was granted on February 11, 2026.
• The transaction is expected to close in the second quarter of 2026, pending remaining regulatory clearances, including from certain European countries and the Japanese competition authority.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development for the merger, as key stockholder and initial regulatory approvals have been secured, significantly de-risking the transaction's completion.

Positives

• Stockholders approved the Merger Proposal, satisfying a key condition for the acquisition by BioMarin Pharmaceutical Inc.
• The non-binding advisory Compensation Proposal related to the Merger was also approved.
• Early termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period was granted by the U.S. Federal Trade Commission on February 11, 2026.

Risks

• The transaction and its financing may not be consummated in the anticipated timeframe, if at all.
• The Merger Agreement could be terminated.
• Various closing conditions for the transaction may not be satisfied or waived, including governmental entities prohibiting, delaying, or refusing approval, or granting approval subject to adverse conditions or limitations.
• The transaction could adversely affect relationships with employees, customers, suppliers, other business partners, or governmental entities, including employee retention.
• Difficulty in predicting the timing or outcome of regulatory approvals or actions.
• Impact of competitive products and pricing.
• BioMarin may not realize the potential benefits of the transaction, or expected benefits may not be realized within the expected time period.
• Integration of Amicus and BioMarin may be more difficult, time-consuming, or costly than expected.
• Disruption of management's time from ongoing business operations due to the transaction.
• The transaction could disrupt current plans and operations.
• Challenges in obtaining and maintaining adequate coverage and reimbursement for Amicus products.
• Changes in Amicus's business during the period between the announcement and closing of the transaction.
• Potential legal proceedings and/or regulatory actions related to the transaction.
• Other business effects, including those from industry, economic, or political conditions outside of the companies' control.
• Costs and expenses related to the transaction.
• Actual or contingent liabilities.
• The transaction (or its announcement) could affect Amicus's and BioMarin's stock price and/or operating results.

Future Outlook

The transaction is expected to close in the second quarter of 2026, subject to the satisfaction or waiver of other customary closing conditions, including receipt of any necessary antitrust and foreign direct investment clearances from non-U.S. or supranational governmental bodies, such as those in certain European countries and Japan.

Industry Context

StockSavvy.ai notes that consolidation within the biotechnology and rare disease sectors remains a significant trend, driven by the pursuit of expanded pipelines, market access, and operational efficiencies. This acquisition by BioMarin, a leader in rare disease therapies, positions Amicus's assets within a larger, more established framework, potentially accelerating product development and commercialization for Amicus's therapies.

Legal Proceedings

• The filing mentions a risk of "any legal proceedings and/or regulatory actions that may be instituted related to the Transaction," but does not disclose any current or ongoing proceedings.

Stakeholder Impact

• Shareholders: The approval of the merger means shareholders will receive the agreed-upon consideration from BioMarin, subject to the transaction closing.
• Employees: There is a risk that the transaction could adversely affect employee retention.
• Customers/Suppliers/Business Partners: There is a risk that the transaction could adversely affect relationships with these parties.

Next Steps

• Obtain remaining regulatory clearances, consents, or affirmative approvals under antitrust and foreign direct investment laws from non-U.S. or supranational governmental bodies (e.g., certain European countries, Japanese competition authority).
• Satisfy or waive other customary closing conditions.
• Complete the transaction, expected in the second quarter of 2026.

Key Dates

Recommendation

The overwhelming stockholder approval and initial regulatory clearance significantly de-risk the merger, making its completion highly probable. Investors currently holding Amicus shares should continue to hold, anticipating the closing of the transaction in Q2 2026 and the receipt of the merger consideration. New investors might find limited upside given the advanced stage of the acquisition, as the share price likely already reflects the agreed-upon acquisition terms, but the remaining regulatory hurdles still present a minor, albeit diminishing, risk.

Keywords

Amicus Therapeutics, BioMarin Pharmaceutical, Merger, Acquisition, Stockholder Vote, SEC Filing, 8-K, Corporate Action, Pharmaceutical, Biotechnology, FOLD, NASDAQ